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(-)-Epigallocatechin-3-gallate (EGCG) is a natural polyphenolic compound of the plant origin. Mafosfamide 
(MAF) belongs to the oxazaphosphorine agents. The aim of the present study was to determine in vitro an-
tileukemic activity of (-)-epigallocatechin-3-gallate (EGCG) and mafosfamide (MAF). The experiments were 
performed on human promyelocytic leukemia HL-60 cells. The research was conducted using spectrophoto-
metric and fl ow cytometric methods. The cell viability was analyzed using spetrophotometric MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) test, and fl ow cytometry FSC/SSC (forward scatter / 
side scatter) and FDA / PI (fl uorescin diacetate / propidium iodide) assays. The infl uence of each tested agent, 
EGCG and MAF, given alone or in combination, on HL-60 cells was assessed. The cytotoxic effects of these 
two polyphenolic and oxazaphosphorine agents on human promyelocytic leukemia cells were dose- and time- 
dependent. EGCG and also MAF, applied alone, affected the leukemia cell viability. The combined action of 
(-)-epigallocatechin-3-gallate and mafosfamide enhanced the antileukemic activity against HL-60 cells. 
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INTRODUCTION
(-)-Epigallocatechin-3-gallate is the ester of gal-
lic acid and epigallocatechin. EGCG is the most 
abundant and biologically active polyphenolic ca-
techin in green tea Camellia sinensis. Among the 
green tea catechins, EGCG is accepted to be the 
strongest chemopreventive and anticancer agent 
(CHEN et al., 2004; CARLSON et al., 2007; GUPTA, et 
al., 2008; MERELEZ and HUNSTEIN, 2011; SINGH et 
al., 2011; KANWAR et al., 2012). Mafosfamide is a 
chemically stable 4-thioethane sulfonic acid salt 
of 4-hydroxy-cyclophosphamide. MAF represents 
a new generation of oxazaphosphorine antican-
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cer agents (LIANG et al., 2007; GIRAUD et al., 2010; 
MAZUR et al., 2012). 
(-)-Epigallocatechin-3-gallate and mafosfa-
mide are potential therapeutic compounds 
for cancer therapy (KHAN and MUKHTAR, 2008; 
GIRAUD et al., 2010; SINGH et al., 2011; MAZUR et 
al., 2012). EGCG as a natural compound could 
be useful either alone or in combination with oth-
er agents for the prevention of cancer progres-
sion and/or treatment of human malignancies. 
Elucidation of biological properties of EGCG and 
MAF can open up an opportunity for the develop-
ment of improved anticancer therapy. Therefore, 
EGCG and MAF have gained signifi cant atten-
tion among scientists, and these agents are still 
under investigation (BANSAL et al., 2012; MAZUR 
et al., 2012, 2013; OPYDO-CHANEK, 2013; BLICHAR-
SKI et al. 2014; KIM et al., 2014).
The cell viability is an important parameter 
characterizing potential antileukemic activity of 
the tested agents. The viability of cell population 
can be determined using spetrophotometric MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide) test, and fl ow cytometry FSC/
SSC (forward scatter / side scatter) and FDA / PI 
(fl uorescin diacetate / propidium iodide) assays. 
Using the MTT assay, in viable, metabolically 
active cells, the tetrazolium ring of 3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide is cleaved, yielding formazan crystals. 
Changes in the metabolic activity and viability of 
cell populations result in a concomitant change 
in the amount of formazan formed. The other via-
bility assay is based on the measurement of light 
scattered by the cells. A cell traversing through 
the focus of the laser beam in a fl ow cytometer 
scatters the laser light. Analysis of the scattered 
light provides information about the cell size and 
structure. The intensity of light scattered in a 
forward direction (FSC) correlates with the cell 
size. The intensity of scattered light measured 
at a right angle to the laser beam (side scatter, 
SSC) correlates with granularity and the pres-
ence of intracellular structures that can refl ect 
the light. The cell’s ability to scatter light is ex-
pected to be altered during cell death. The FDA/
PI assay of membrane integrity employs the non-
fl uorescent esterase substrate, fl uorescein diace-
tate and propidium iodide. Fluorescein diacetate, 
after being taken up by live cells, is hydrolyzed 
by intracellular esterases. The product of the 
hydrolysis, fl uorescein, is a highly fl uorescent, 
charged molecule which becomes trapped in in-
tact cells. Propidium iodide is excluded by an in-
tact membrane (DARŻYNKIEWICZ et al., 1997). 
The present study was undertaken to assess 
the antileukemic activity of (-)-epigallocatechin-
3-gallate and mafosfamide, applied alone or in 
combination, against human promyelocytic leu-
kemia cells. The cell viability of HL-60 cells ex-
posed to the action of EGCG and/or MAF was 
analyzed using spectrophotometry and fl ow cyto-
metry assays.
MATERIALS AND METHODS
 Cells
Human promyelocytic leukemia HL-60 cells 
(American Type Culture Collection, Rockville, 
MD, USA) were maintained in RPMI 1640 medi-
um (Gibco BRL Life Technologies), supplemented 
with 10% fetal calf serum (GIBCO BRL Life Tech-
nologies), 2 mM L-glutamine (Sigma Aldrich), 
and antibiotic antimycotic solution (AAS, Sigma 
Aldrich). AAS contained 20 units of penicillin, 
20 μg streptomycin and 0.05 μg amphotericin B. 
Every third day, HL-60 cells were passaged. The 
cells grew at 37°C in an atmosphere of 5% CO2 in 
air (HERAcell incubator, KendroLab).
 Chemicals
(-)-Epigallocatechin-3-gallate (EGCG, Sigma) 
and mafosfamide cyclohexylamine salt (MAF, 
NIOMECH, Bielefeld, Germany) were used. 
EGCG and MAF were dissolved in 0.9 % NaCl 
(Polpharma). All the solutions were freshly pre-
pared directly before the treatment of the leuke-
mia HL-60 cells.
Agent doses and cell treatment
After diluting the cell suspension to a density 
of 15×104 cells/ml medium, HL-60 cells were ex-
posed simultaneously to the action of EGCG and 
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MAF. Based on the unpublished data, the doses 
of the tested compounds were chosen. (-)-Epigal-
locatechin-3-gallate was given at two single doses 
of 25 μg/ml and 50 μg/ml of the complete RPMI 
1640 medium. Mafosfamide cyclohexylamine salt 
was applied at a single dose of 15 μg/ml of the 
complete RPMI 1640 medium. EGCG and also 
MAF were given alone, as well as both these 
agents were applied in combination. The control 
material consisted of untreated HL-60 cells. 
Analyses of HL-60 cell viability after EGCG 
and/or MAF application
The cell viability of HL-60 cells was analyzed at 
24 h and 48 h after the EGCG and/or MAF ap-
plication. The research was conducted using the 
spectrophotometry and fl ow cytometry assays.
Spectrophotometric MTT assay
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide (Sigma-Aldrich) was dissolved in 
RPMI 1640 medium, at a concentration of 5 mg/
ml and fi ltered through a 0.2 μm fi lter. Subse-
quently, 100 μl of the yellow MTT solution was 
added to each well of a 24-well plate, containing 
1 ml of the cell suspension. The cells were then 
incubated at 37°C with 5% CO2. A blank solu-
tion was prepared according to the above proce-
dure using complete medium without cells. Af-
ter a three-hour incubation period, the resulting 
formazan crystals were dissolved using 1 ml of 
acidifi ed isopropanol (0.05 N HCL in absolute iso-
propanol), and the absorbance of the obtained so-
lution was measured at a wavelength of 570 nm 
using a Pharmacia Ultrospec III spectrophoto-
meter (Pharmacia LKB Biotechnology).
Cell viability assay by light scatter 
measurement
The cell suspension was centrifuged at 1000 rpm 
(MPW-351RH centrifuge, Med. Instruments) for 
7 min at 4°C. The cell pellet was resuspended 
in 500 μl of cold PBS, and forward scatter and 
side scatter were immediately measured using 
a FACSCalibur fl ow cytometer (Becton Dickin-
son) to detect changes in the cell size and gran-
ula-rity, respectively. Data were analyzed using 
CellQuest Pro software (Becton Dickinson). The 
frequency of three cell populations, FSC high/
SSC low, FSC low/SSC high, and FSC high/SSC 
high, was determined.
Flow cytometry FDA/PI assay
The cell suspension containing 5×105 cells was 
centrifuged at 1000 rpm (MPW-351RH centri-
fuge, Med. Instruments) for 7 min, and the cell 
pellet was resuspended in 1 ml of warm HBSS 
(Invitrogen). Then, 10 μl of FDA working solu-
tion (at a concentration of 1 μg/ml of HBSS) was 
added and the cells were incubated in the dark 
for 15 min at 37°C. After incubation with FDA, 
20 μl of PI working solution (at a concentration of 
30 μg/ml of 0.9% NaCl) was added, and the cells 
were incubated for additional 5 min. Incubation 
of cells in the presence of both FDA and PI labels 
live cells green and dying cells red. Cell samples 
were placed on ice, away from light, and FDA 
and PI fl uorescence was immediately measured 
using a FACS Calibur fl ow cytometer. Data were 
analyzed using CellQuest Pro software. The 
frequency of three cell populations, FDA+/PI-, 
FDA-/PI-, and FDA-/PI+, was determined. 
Statistical evaluation
Statistical signifi cance of alterations in the ana-
lyzed parameters was evaluated by an analysis 
of variance and Duncan’s new multiple range 
test. A difference with P<0.05 was considered 
statistically signifi cant.
RESULTS
The effects of (-)-epigallocatechin-3-gallate and/
or mafosfamide on the viability of human pro-
myelocytic leukemia HL-60 cells were deter-
mined using spectrophotometric MTT test, and 
FSC/SSC and FDA/PI fl ow cytometry assays. 
The different patterns of temporary changes in 
the cell viability rate (Fig.1), size and granula-
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rity (Fig. 2) and membrane integrity (Fig.3) were 
observed at 24 h and 48 h after the application 
of EGCG, at two doses of 25 μg/ml and 50 μg/ml, 
and/or MAF at a dose of 15 μg/ml of medium. 
The exposure of HL-60 cells to the action of 
EGCG and MAF, applied only, and also in com-
bination, distinctly decreased the viability rate 
of HL-60 cells (Fig.1). The combined applica-
tion of EGCG and MAF affected the leukemia 
cell viability to a higher degree than did each 
of the tested agent given alone. The infl uence of 
the combined action of the catechin and oxaza-
phosphorine agents on the HL-60 cell viability 
rate was dependent on the dose of EGCG.
Distinct changes in the cell size and granular-
ity of HL-60 cells were found (Fig.2). The expo-
sure of HL-60 cells to the action of EGCG and 
MAF, applied only and in combination, resulted 
in a decrease in the frequency of the FSC high/
SSC low cell population and an increase in the 
percentage values of two cell populations, FSC 
low/SSC high and FSC high/SSC high. 
The application of EGCG and MAF distinctly 
affected the membrane integrity of HL-60 cells 
(Fig.3). After exposure of HL-60 cells to the ac-
tion of EGCG and MAF, applied alone and in 
combination, signifi cant changes in the frequen-
cy of FDA+/PI-, FDA-/PI-, and FDA-/PI+ cell 
populations were assessed. The distinctly lower 
frequency of FDA+/PI- cell population and the 
signifi cantly higher frequency of two cell popu-
lations, FDA-/PI- and FDA-/PI+, were observed 
after the combined action of EGCG and MAF as 
compared with the percentage values found after 
the application of each of the tested agent only. 
DISCUSSION
The results of the present study have shown 
various in vitro antileukemic activities of (-)-epi-
gallocatechin-3-gallate and mafosfamide against 
HL-60 cells. The cytotoxic effects of EGCG and 
MAF on human promyelocytic leukemia cells 
were dose- and time-dependent. Moreover, it 
should be underlined that the combined action 
of EGCG and MAF affected the HL-60 cell via-
bility to a greater degree than did each of the 
tested agent, polyphenolic catechin and oxaza-
phosphorine. 
The mechanisms of action of (-)-epigallocate-
chin-3-gallate and mafosfamide have been exten-
sively investigated in recent years. The cell re-
sponse to the action of EGCG and MAF was deter-
mined at the molecular, biochemical, and cellular 
levels. Nevertheless, the modes of their action on 
the cells have not been fully explained yet (KHAN 
et al., 2006, 2008; SINGH et al., 2011; BANSAL et al., 
2012; MAZUR et al., 2012, 2013; OPYDO-CHANEK et 
al., 2013; BLICHARSKI et al., 2014; KIM et al., 2014).
(-)-Epigallocatechin-3-gallate, a polyphenolic 
agent, is often classifi ed as an anti-oxidant acting 
by scavenging reactive oxygen and nitrogen spe-
cies and chelating redox-active transition metal 
ions. However, EGCG also functions as a pro-oxi-
dant producing hydrogen peroxide and hydroxyl 
radicals. The anti-oxidant or pro-oxidant action 
of EGCG depends on its dose and the cell type 
and status (GUPTA et al., 2008; KIM et al., 2014). 
Recent studies have revealed many other direct 
actions of EGCG which alter the physiological re-
sponses of cells (FENG, 2006; GUPTA et al., 2008; 
KIM et al., 2014). Catechin modulates several key 
molecular signaling pathways at multiple levels, 
and regulates transcription factors, DNA methy-
lation. EGCG can directly interact with a large 
set of proteins and phospholipids in the plasma 
membrane, and affects mitochondrial function. 
The action of this polyphenolic agent results in 
the cell cycle arrest and induction of programmed 
Fig. 1. Effects of EGCG and MAF on the HL-60 cell viability 
rate. The extent of MTT conversion in HL-60 cells expressed 
as a percentage of the control value. The data are presented as 
mean values ± SD. Values not signifi cantly different at P<0.05: 
* between the groups of leukemia cells treated with the tested 
agent(s); # compared to controls; + between the time points. 
EGCG 25 – EGCG applied at a dose of 25 μg/ml medium; 
EGCG 50 – EGCG given at a dose of 50 μg/ml medium; MAF 
15 – MAF applied at a dose of 25 μg/ml medium.
83Antileukemic Activity of EGCG and MAF
Fig. 2. Effects of EGCG and MAF on the light scattering properties of HL-60 cells. Flow cytometry analysis shows changes in 
the cell size (forward scatter, FSC on the x-axis) and granularity (side scatter, SSC on the Y-axis). Representative dot plots for 
HL-60 cells (A) and the values of FSC high/SSC low, FSC low/SSC high and FSC high/SSC  high (B). The obtained data (B) are 
presented as mean values ± SD. Values not signifi cantly different at P<0.05 :* between the groups of leukemia cells treated 
with the tested agent(s); # compared to controls; + between the time points. EGCG 25, 50; MAF 15 – see description Fig.1.
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Fig. 3. Effects of EGCG and MAF on the HL-60 cell viability analyzed using the fl ow cytometry FDA/PI assay. Representative 
dot plots for HL-60 cells stained with fl uorescein diacetate FDA (FL1-H – fl uorescence of FDA) and propidium iodide PI (FL3-H 
– fl uorescence of PI). The data are presented as mean values ±SD. No statistically signifi cant differences (P<0.05) between the 
values shown on dot plots : III – (3); IV – (4); V– (5); VI– (6); IX – (9); XI – (11); XII – (12). The value not signifi cantly different 
from 24h – 24h; 48h - 48h. EGCG 25, 50, MAF 15 – see description Fig.1.
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cell death (KHAN et al., 2006, 2008; SINGH et al., 
2011; KANWAR et al., 2012; BLICHARSKI et al., 2014; 
KIM et al, 2014).
Mafosfamide, an oxazaphosphorine agent, is a 
pre-activated cyclophosphamide analog. The ef-
fects of MAF on cells are accepted as being depen-
dent mainly on its metabolites, phosphoramide 
mustard and acrolein. These reactive alkylating 
agents can bind to a variety of molecules and react 
with available groups of amino acids, proteins and 
peptides, but the DNA binding site is most impor-
tant. MAF caused the disruption of DNA function, 
the cell cycle disturbance and induced mitotic ca-
tastrophe and programmed cell death (ZHANG et al., 
2005; LIANG et al., 2007; GIRAUD et al., 2010; MAZUR 
et al., 2012, 2013; OPYDO-CHANEK et al., 2013).
 A better understanding of the exact mecha-
nisms of action of (-)epigallocatechin-3-gallate 
and mafosfamide, given only and in combina-
tion, on the pathological hematopoietic cells is of 
great importance in experimental hematology. 
Elucidation of the modes of the combined action 
of EGCG and MAF can contribute to the develop-
ment of more specifi c strategies against hemato-
logical malignancies.
To summarize, the research has revealed the 
effects of (-)-epigallocatechin-3-gallate and ma-
fosfamide, applied alone or in combination, on 
temporary changes in the viability of human pro-
myelocytic leukemia HL-60 cells. These are the 
fi rst data showing the antileukemic potential of 
the combined action of EGCG and MAF. 
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